Антифосфолипидный синдром - часть 81

329

12. Jacobsen S, Petersen J, Ullman S, et al.

Mortality and causes of death of 513 Danish
patients with systemic lupus erythematosus. Scand
J Rheumatol 1999; 28: 75—80. 

13. Gripenberg M, Helve T. Outcome of sys

temic lupus erythematosus: a study of 66 patients
over 7 years with special reference to the predic
tive value of antiDNA antibody determinations.
Scand J Rheumatol 1991; 20: 104—109. 

14. Cervera R, Khamashta MA, Font J, et al.

Morbidity and mortality in systemic lupus erythe
matosus during a 5year period: a multicenter
prospective study of 1000 patients. Medicine
1999; 78: 167—175.

15. Ward MM, Pyun E, Studenski S. Long

term survival in systemic lupus erythematosus:
patient characteristics associated with poorer out
comes. Arthritis Rheum 1995; 38: 274—283. 

16. Ward MM, Pyun E, Studenski S. Causes of

death in systemic lupus erythematosus: longterm
followup of an inception cohort. Arthritis Rheum
1995; 38: 1492—1499. 

17. Pistiner M, Wallace DJ, Nessim S, et al.

Lupus erythematosus in the 1980s: a survey of
570 patients. Semin Arthritis Rheum 1991; 21:
55—64. 

18. Gudmundsson S, Steinsson K. Systemic

lupus erythematosus in Iceland 1975 through
1984: A nationwide epidemiological study in an
unselected population. J Rheumatol 1990; 17:
1162—1167.

19. StahlHallengren C, Jonsen A, Nived O, et

al. Incidence studies of systemic lupus erythe
matosus in southern Sweden. increasing age,
decreasing frequency of renal manifestations and
good prognosis. J Rheumatol 2000; 27: 685—
691.

20. Насонов ЕЛ, Карпов ЮА, Алекберова ЗС

и соавт. Антифосфолипидный синдром: кар
диологические аспекты. Терапевт. архив
1993; 11: 80—86.

21. Насонов ЕЛ. Атеротромбоз при ревма

тических заболеваниях: анализ патогенеза.
Терапевт. архив, 1998; 9: 92—95.

22. Насонов ЕЛ. Проблема атеротромбоза в

ревматологии. Вестник РАМН, 2003; 7: 6—
10.

23. Petri M, Spence D, Bone LR, Hochberg

MC. Coronary artery disease risk factors in the

John Hopkins Lupus Cohort: prevalence, recog
nition by patients, and preventing practices.
Medicine 1992; 71: 291—302. 

24. Urowitz MB, Gladman DD. How to improve

morbidity and mortality in systemic lupus erythe
matosus. Rheumatology 2000; 39: 238—244.

25. Aronov C, Ginzler EM. Epidemiology of

cardiovascular disease in systemic lupus erythe
matosus. Lupus 2000; 9: 166—169.

26. Manzi S, Meilahn EN, Rairie JE et al. Age

specific incidence rates of myocardial infarction
and angina in women with systemic lupus erythe
matosus: comparison with the Framingem study.
Am J Epidemiol 1997; 145:408—415.

27. Manzi S. Systemic lupus erythematosus: a

model for atherogenesis? Rheumatology 2000; 39:
353—359.

28. Salmon JE, Roman MJ. Accelerated ather

osclerosis in systemic lupus erythematosus: impli
cations for patientas management. Curr Opin
Rheumatol 2001; 13: 341—344.

29. Bruce IN, Gladman DD, Urowitz MB.

Premature atherosclerosis in systemic lupus ery
thematosus. Rheum Dis Clin North Amer 2000;
26: 257—278.

30. Manzi S, Wasco MCM. Inflammation

mediated rheumatic disease and atherosclerosis.
Ann Rheum Dis 2000; 59: 321—325.

31. Urowitz M, Gladman D, Bruce I. Athero

sclerosis and Systemic Lupus Erythematosus.
Curr Opin Rheumatoе 2000; 2: 19—23.

32. Jimenez S, RamosCassals M, Cervera R,

et al. Atherosclerosis in systemic lupus erythe
matosus: clinical relevance In. Atherosclerosis
and autoimmunity Ed. Y Schoenfeld, D. Harats,
G Wick. Elsevier 2001: 255—265.

33. Thomas GN, Tam LS, Tomlinson B, Li EK.

Accelerated atherosclerosis in patients with sys
temic lupus erythematosus: a review of the cause
and possible prevention. HKMJ 2002; 8: 26—32.

34. Urowitz MB, Bookman AAM, Koehler BE:

The bimodal mortality pattern of systemic lupus
erythematosus. Am J Med 1976, 60: 221—225.    

35. Roman MJ, Shanker BA, Davis A, et al.

Prevalence and correlates of accelerated athero
sclerosis in systemic lupus erythematosus. New
Engl J Med 2003; 349: 2399—2406.

36. Asanuma Y, Oeser A, Shintani AK, et al.

Premature coronaryartery atherosclerosis in sys

ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС

Насонов Е.Л. Антифосфолипидный синдром

330

temic lupus erythematosus. New Engl J Med
2003; 349: 2407—2415.

37. Badui E, GarciaRubi D, Robles E, et al.

Cardiovascular manifestations in systemic lupus
erythematosus: prospective study in 100 patients.
Angiology 1985; 36: 431—441.

38. Gladman DD, Urowitz MB. Morbidity in

systemic lupus erythematosus. J Rheumatol 1987;
14; S13: 223—226

39. Jonsson H, Nived O, Sturfeit G. Outcome in

systemic lupus erythematosus: a prospective study
of patients from defined population. Medicine
(Baltimore) 1989; 42: 338—346.

40. Petri M, PerezGutthann S, Spence D,

Hochberg MC. Risk factor for coronary arthery
disease in patients with systemic lupus erythe
matosus. Am J Med 1992; 93: 513—519.

41. HeartHolmes M, Baethege BA, Brooadwell

L, Wolf RE. Dietary treatment of hyperlipidemia
in patients with systemic lupus erythematosus. J
Rheumatol 1995; 22: 450—454.

42. Ward MM. Premature morbidity from car

diovascular disease in women with systemic lupus
erythematosus. Arthritis Rheum 1999; 42: 338—
346.

43. Petri M. Cardiovascular morbidity in the

Hopkins Lupus Cohort. In. Atherosclerosis and
autoimmunity Ed. Y Schoenfeld, D Harats, G
Wick. Elsevier 2001; 249—254.

44. Bruce IN, Urowitz MB, Gladman DD,

Hallett DC. Natural history of hyperlipidemia in
systemic lupus erythematosus. J Rheumatol 1999;
26: 2137—2143.

45. Bruce IN, Urowitz MB, Gladman DD, et al.

Risk factors for coronary heart disease in women
witn systemic lupus erythematosus. Arthritis
Rheum 2003; 48: 3159—3167.

46. Doria A, Shoenfeld Y, Wu R, et al. Risk fac

tors for subclinical atherosclerosis in a prospective
cohort of patients with systemic lupus erythemato
sus. Ann Rheum Dis 2003; 62: 1071—1077.

47. Ettinger WH, Goldberg MD, Applebaum

Bowdwn D, Hazzard WR. Dyslipoproteinemia in
systemic lupus erythematosus. Effect of corticos
teroids. Am J Med 1987; 83: 503—508.

48. Leong KH, Koh ET, Feng PH, Boey ML.

Lipid profiles in patients with systemic lupus ery
thematosus. J Rheumatol 1994; 21: 1261—
1267.

49. Ilowite NT, Samuel P, Ginzler E. Dyslipopro

teinemia in pediatric systemic lupus erythematosus.
Arthritis Rheum 1988; 31: 859—863.

50. Borba EF, Bonfa E. Dyslipoproteinemias in

systemic lupus erythematosus: influence of dis
ease, activity and anticardiolipin antibodies.
Lupus 1997; 6: 533—539. 

51. Алекберова ЗС, Попкова ТВ, Насонов

ЕЛ, Решетняк ТМ, Озерова ИН, Перова НВ.
Липидбелковые системы транспорта холес
терина у больных системной красной волчан
кой в зависимости от антифосфолипидного
синдрома. Терапевт. архив, 1999; 5: 34—38.

52. Formiga F, Meco JF, Pinto X, et al. Lipid

and lipoprotein levels in premenopausal systemic
lupus erythematosus patients Lupus 2001; 10:
359—363.

53. Borba E, Bonfa E, Vinagre CGC, et al.

Chylomicron metabolism is marfedly altered in
systemic lupus erythematosus. Arthritis Rheum
2000; 43: 1033—1040.

54. Eder HA, Gidez LI. The clinical signifi

cance of the plasma high density lipoproteins.
Med Clin N Amer 1982; 66: 431—440.

55. Nuttall SL, Heaton S, Piper MK, et al.

Cardiovascular risk in systemic lupus erythe
matosus — evidence of increased oxidative stress
and dislipidaemia. Rheumatology 2003; 42:
758—762.

56. Svenungsson E, JensenUrstad K,

Heimburger M, et al. Risk factors for cardiovas
cular disease in systemic lupus erythematosus.
Circulation 2001; 104: 1887—1893.

57. Danesh J, Collins R, Peto R. Lipoprotein(a)

and coronary heart disease. Metaanalysis of
prospective studies. Circulation 2000; 102:
1082—1085.

58. Petri M, Miller J, Ebert RF. Lipoprotein a

(Lp[a]) is predictive of myocardial infarction in
SLE. Arthritis Rheum 1995; 38 (Suppl 9): S220. 

59. Leandro MI, Atsumi T, Khamashta M, et

al. High plasma levels of lipoprotein(a) in patients
with primary and secondary antiphospholipid
syndrome. Arthritis Rheum. 1996; 39 (Suppl): 96
(abst.)

60. Yamazaki M, Asakura H, Jokaji H, et al.

Plasma levels of lipoprotein (a) are elevated in
patients with antiphospholipid antibody syn
drome. Thromb Haemost 1994; 71: 424—427.

331

61. Petri M. Thrombosis and systemic lupus

erythematosus: the Hopkins lupus cohort perspec
tive. Scand J Rheumatol 1996; 25: 191—193.

62. Попкова ТВ, Покровский СН, Алекберо

ва ЗС, Фомичева ОА, Александрова ЕН,
Клюквина НГ, Насонов ЕЛ. Липопротеин (а)
при системной красной волчанке. Клин. меди
цина, 1998; 1: 21—24.

63. Font J, RamosCasals, Cervera R, et al.

Cardiovascular risk factors and longterm out
come of lupus nephritis. Q J Med 2001; 94: 19—
26.

64. Bono L, Cameron JS, Hicks JA. The very

longterm prognosis and complications of lupus
nephritis and its treatment. Q J Med 1999; 92:
211—218.

65. Falaschi F, Ravelli A, Martignon A, et al.

Nephroticrange proteinuria, the major risk fac
tor for early athrosclerosis in juvenileonset sys
temic lupus erythematosus. Arthritis Rheum 2001;
43: 1405—1409.

66. Kannell WB, Wolf PA, Castelli WP,

D`Agostino RB. Fibrinogen and risk of cardiovas
cular disease. The Framingham Study. J Am Med
Assoc 1987; 258: 1183—1186.

67. Rahman P, Urowitz MB, Gladman DD, et

al. Contribution of traditional risk factor to coro
nary artery disease in patients with systemic lupus
erythematosus. J Rheumatol 1999; 26: 363—368.

68. Esdale JM, Abrahamowicz M, Grodzicky T,

et al. Traditional Framingham Risk factor fail to
fully account for accelerated atherosclerosis in
systemic lupus erythematosus. Arthritis Rheum
2001; 44: 2331—2337.

69. Font J, Jimenez S, GarciaCriado A, et al.

Atherosclerosis in SLE is associated with cumula
tive disease damage but not with traditional vas
cular risk factors. ACR 2002; 42 (abst).

70. Marwick TH, Anderson T, Williams MJ, et

al. Exercise echocardiography is an accurate and
costeffective technique for detection of coronary
artery disease in women. J Am Coll Cardiol 1995;
26: 335—341.

71. Kwok Y, Kim C, Grady D, Segal M,

Redberg R. Metaanalysis of exercise testing to
detect coronary artery disease in women. Am J
Cardiol 1999; 83: 660—666.

72. Hosenpud JD, Montanaro A, Hart MV:

Myocardial perfusion abnormalities in asympto

matic patients with systemic lupus erythematosus.
Am J Med 1984, 77: 286—792.

73. Shome GP, Sakauchi M, Yamane K.

Ischemic heart disease in systemic lupus erythe
matosus. A retrospective study of 65 patients treat
ed with prednisolone. Jpn J Med 1989; 28: 599—
603.

74. Bruce IN, Burns RJ, Gladman DD, Urowitz

MB. A study of myocardial perfusion abnormali
ties in women with SLE. J Rheumatol 1998;
25(Suppl 52): 72. 

75. Самойленко ЛЕ, Фомичева ОА, Насонов

ЕЛ и соавт. Состояние микроциркуляции ми
окарда у больных системной красной волчан
кой. Терапевт. архив, 2001; 5: 29—31.

76. Berman DS, Kiat H, Freidman JD. Separate

acquisition rest thallium—201/technetium

99m

sestamibi dualisotope myocardial perfusion sin
glephoton emission computed tomography: a clin
ical validation study. J Am Coll Cardiol 1993,
22:1455—1464.

77. San SS, Shiau YX, Tsai SC, et al. The

role of technetion

99m

setanibi myocardial perfu

sion singlephoton emission computed tomogra
phy (SPECT) in the detection of cardiovascular
involvement in systemic lupus erythematosus
patients with nonspecific chest complaints.
Rheumatology 2001; 40: 1106—1111.

78. Schillaci O, Lagana B, Danieli R, et al.

Technetiom

99m

sestamibi single photonemission

tomography defects subclinical myocardial perfu
sion abnormalities in patients with systemic lupus
erythematosus. Eur J Nucl Med 1999; 26: 713—
717. 

79. Taquet A, BonithonKnopp C, Simon A, et

al. Relations of cardiovascular risk factors to aor
tic pulse wave velocity is asymptomatic middle
aged women. Eur J Epidemiol 1993; 9: 298—306.

80. Seilzer F, SuttonTyrrell K, Fitzgerald S, et

al. Vasculat stiffness in women with systemic lupus
erythematosus. Hypertension 2001; 37: 1075—
1082.

81. Detrano RC, Wong ND, Doherty TM, et al.

Coronary calcium does not accurately predict
nearterm future coronary events in hifhrisk
adults. Circulation 1999: 2633—2638.

82. O`Rourke RA, Brundage BH, Froelicher

VF, et al. ACC/AHA expert consensus document
on electronbeam computed tomography for the

ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС

Насонов Е.Л. Антифосфолипидный синдром

332

diagnosis and pognosis of coronary artery disease.
Circulation 2000; 102: 126—140.

83. Park R, Detrano R, Xiang M, et al.

Combined use of computed tomography coronary
calcium score and Creactive protein levels in
predicting cardiovascular events in nondiabetic
individuals. Circulation 2002; 10: 2073—2089.

84. Sherer Y, Shemesh J, Tenenbaum A, et al.

Coronary calcium and anticardiolipin antibody
are elevated in patients with typical chest pain.
Am J Cardiol 2000; 86:1306—1311.

85. Scalzi LV, VonFeldt JM. Electrone Beam

computer tomography as a tool to identification
asymptomatic coronary atherosclerosis in SLE
patients. ACR 64th Annual Scientific Meeting
2000; 33(abst).

86. Turner ELS, Oeser A. Asunuma Y, et al.

Premature coronary atherosclerosis in systemic
lupus erythematosus is not related in disease
activity or corticosteroid rherapy. ACR 66th
Annual Scientific Meeting, October 24—29,
2002; 36 (abst).

87. Petri M. Noninvasive test for atherosclerosis

in SLE. ACR 65 th Annual Scientific Meeting,
November 10—15, 2001; 1671 (abst).

88. Petri M. Cardiovascular risk factors and

coronary calcification (CC) in systemic lupus
erythematosus. ACR 65 th Annual Scientific
Meeting, November 10—15, 2001; 1409
(abst).

89. Von Velt JM, Eisner ER, Sawaires A.

Coronary electron beam computed tomography in
13 patients with systemic lupus erythematosus and
two or more cardiovascular risk factors. J Clin
Rheumatol 2002; 8: 316—321.

90. Manger K, Kukus M, Foster C, et al. Risk

factors for coronaryartery calcification in
females with systemic lupus erythematosus below
of age 50. ACR 65 th Annual Scientific Meeting
November 10—15, 2001; 1408 (abst). 

91. Flagg SD, Scalzi LV, van Dyke AL, et al.

Homocystein and number of traditional cardio
vascular risks predict coronary artery calcifica
tion in SLE. ACR/ARHP Annual Scientific
Meeting October 24—28, 2003; 887 (abst).

92. Petri M, Kiani AN. Coronary calcium in SLE

is due to inflammation, not lipid. ACR/ARHP
Annual Scientific Meeting October 24—28, 2003;
889 (abst). 

93. Lima DSN, Sato EI, Lima VC, et al.

Brachial endothelial function is impaired in
patients with systemic lupus erythematosus. J
Rheumatol 2002; 29: 292—297.

94. De Lеeuw K, Freire B, Smith AJ, et al.

Premature atherosclerosis and endothelial dys
function in systemic lupus erythematosus. ACR
66th Annual Scientific Meeting October 25—29,
2002; 44 (abst).

95. Rajagopalan S, Somers E, Brook R, et al.

Abnormal endothelial function in females with
lupus correlates with circulating apoptotic
endothelial cells. ACR/ARHP Annual Scientific
Meeting October 24—28, 2003; 897 (abst). 

96. Mancini J. Carotid intimamedis thickness

as a measure of vascular target organ damage.
Curr Hypertension Reports 2000; 2: 71—77.

97. O`Leary DH, Polak JF, Kronman RA, et al.

Carotideartery intima media thickness as a risk
factor for myocardial infarction and stroke in
older adults. New Engl J Med 1999; 340: 14—22.

98. Bots ML, Hoes AW, Koudstaal PJ, et al.

Common carotid intimamedia thickness and risk
of stroke and myocardial infarction. Circulation
1997; 96: 1432—1437.

99. Manzi S, Selzer F, SuttonTyrrell K, et al.

Prevalence and risk factors of carotid plaque in
women with systemic lupus erythematosus.
Arthritis Rheum 1999; 42: 51—60.

100. Roman MJ, Salmon JE, Sobel R, et al.

Prevalence and relation to risk factors of carotid
atherosclerosis and left ventricular hypertrophy in
systemic lupus erythematosus and antiphospho
lipid antibody syndrome. Am J Cardiol 2001; 87:
663—666.

101. Vlachoyinnopoulos PG, Kanellopoulos

PG, Ioannidis JPA, et al. Atherosclerosis in pre
menopausal women with antiphospholipid syn
drome and systemic lupus erythematosus: a con
trolled study. Rheumatology 1003; 42: 645—651. 

102. Medina G, Casaos D, Jata LJ, et al.

Increased carotid artery intimamedia thickness
may be associated with stroke in primary
antiphospholipid syndrome. Ann Rheum Dis
2003; 62: 607—610.

103. Ames PRL, Margarita A, Delgado Alves J,

et al. Anticardiolipin antibodies and plasma
homocysteine levels independently predict intima
media thickness of carotid artery in subject with